Dapivirine Ring: Phase III Results

Overview of results: Two large clinical trials — The Ring Study and ASPIRE — showed in 2016 that IPM's monthly vaginal ring containing the antiretroviral drug dapivirine can help reduce women's HIV-1 risk by approximately 30 percent overall and is safe for long-term use.

Greater HIV risk reduction associated with increased ring use: Participants who used the ring at least some of the time saw their HIV infection risk cut by 45 percent across both studies.

Next steps for the ring: IPM, the ring's developer, is pursuing approvals from global and national regulatory authorities to license the product in countries where women face the highest risk. 

Two open-label extension studies, DREAM and HOPE, are providing the ring to former Ring Study and ASPIRE participants, respectively. Both studies were launched in July 2016 and are expected to be completed by December 2018.

First-long-acting HIV prevention method: The dapivirine ring could be an important new self-initiated option for women, who bear the greatest burden of the global HIV/AIDS epidemic.

Impact: Modeling studies show that microbicides like the dapivirine ring would be cost-effective and have a significant public health impact as part of a broader toolkit that could avert tens of millions of HIV infections over time.

Learn more about the results from the Phase III dapivirine ring studies: